No "overall" CV risk increase, but RECORD trial remains controversial

Links shared publicly online about this topic.

  • 1,991
    total visits

No "overall" CV risk increase, but RECORD trial remains controversial

theheart.org —

The trial concluded with the rosiglitazone being

View full resource at theheart.org

Tags: Diabetes Type 2 Medication, Diabetes Medication, Avandia, Avandamet, Avandaryl

  • Share

Most Recently Shared on June 5, 2009 at 11:58 pm By:

theheartorg Shelley Wood

heartwire: Avandia on the RECORD: No "overall" CV risk increase, but trial remains controversial http://bit.ly/oZ6eA

3 years ago...

Reply

Retweet

Favorite

Advertisement